Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q3 2011

Description: Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q3 2011

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q3 2011', provides an overview of the Gastrointestinal Stromal Tumors (GIST) therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Stromal Tumors (GIST), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumors (GIST). 'Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Stromal Tumors (GIST).
- A review of the Gastrointestinal Stromal Tumors (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastrointestinal Stromal Tumors (GIST) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumors (GIST).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumors (GIST) pipeline depth and focus of Gastrointestinal Stromal Tumors (GIST) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumors (GIST) Overview
Therapeutics Development
An Overview of Pipeline Products for Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumors (GIST) Therapeutics under Development by Companies
Gastrointestinal Stromal Tumors (GIST) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Products under Development by Companies
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Gastrointestinal Stromal Tumors (GIST) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
GlaxoSmithKline plc
Novartis AG
ImClone Systems Incorporated
Astex Therapeutics Limited
Bayer AG
AÉterna Zentaris Inc.
OncoVista Innovative Therapies, Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Ambit Biosciences Corporation
Deciphera Pharmaceuticals, LLC
AB Science
Gastrointestinal Stromal Tumors (GIST) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Motesanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Regorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-3G33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT13387 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ganetespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OVI-237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARO-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Yondelis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Regorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glivec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FOLFOX + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Floxuridine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Floxuridine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dasatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glivec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + 5-Fluorouracil + Streptozotocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Semaxanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nilotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Capecitabine + Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-interferon alfa-2b + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-interferon alfa-2b + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec + Nilotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GDC-0449 + RO4929097 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Votrient - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nilotinib + Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + 5-fluorouracil + Leucovorin + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT13387 + Imatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib Malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gastrointestinal Stromal Tumors (GIST) Therapeutics – Drug Profile Updates
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Discontinued Products
Gastrointestinal Stromal Tumors (GIST) - Featured News
Jun 29, 2011: Threshold Initiates Phase I/II Clinical Trial Evaluating TH-302 In Combination With Sunitinib
Jun 06, 2011: Synta Announces Phase II Results Of Ganetespib In Gastrointestinal Stromal Tumors At ASCO
May 18, 2011: Synta Announces Ganetespib Clinical Data Presentations At ASCO 2011 Annual Meeting
May 10, 2011: Bayer Receives FDA Fast Track Designation For Regorafenib For Treatment Of Gastrointestinal Stromal Tumors
Feb 04, 2011: Bayer Wins FDA Orphan Drug Designation For Regorafenib For Treatment Of Gastrointestinal Stromal Tumors
Sep 27, 2010: Pfizer’s Sutent fails in prostate cancer trial
Aug 24, 2010: Pfizer’s Sutent fails in lung cancer test
Mar 12, 2010: Pfizer’s Sutent fails in breast cancer trials
Mar 20, 2009: Oncolytics Biotech (ONCY) Collaborators Update Combination REOLYSIN and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN And Docetaxel Results At iSBTc Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Gastrointestinal Stromal Tumors (GIST), Q3 2011
Products under Development for Gastrointestinal Stromal Tumors (GIST) – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
F. Hoffmann-La Roche Ltd., 2011
Biogen Idec Inc., 2011
Amgen Inc., 2011
GlaxoSmithKline plc, 2011
Novartis AG, 2011
ImClone Systems Incorporated, 2011
Astex Therapeutics Limited, 2011
Bayer AG, 2011
List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumors (GIST), Q3 2011
Products under Development for Gastrointestinal Stromal Tumors (GIST) – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1863297/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets, 
Guinness Centre, 
Taylors Lane, 
Dublin 8, 
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gastrointestinal Stromal Tumors (GIST) - Pipeline Review, Q3 2011
Web Address: http://www.researchandmarkets.com/reports/1863297/
Office Code: SCD2LPK7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 500</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 1000</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 1500</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World